相关临床试验
0
0 进行中
药物批准
5
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll. - The landmark trial will evaluate vaccine efficacy across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants over two years. - India currently has no licensed dengue vaccine or antiviral treatment, making this development critical for addressing a major public health challenge in a country ranking among the top 30 globally for dengue incidence. - The vaccine is based on tetravalent dengue vaccine strains originally developed by the National Institutes of Health (NIH), USA, with Panacea Biotec holding process patents for their formulation work.
- The Phase 3 clinical trial for 'DengiAll,' India's first indigenous tetravalent dengue vaccine developed by Panacea Biotec and ICMR, has begun at KIMS, Bhubaneswar. - The trial will assess the vaccine's efficacy against all four serotypes of the dengue virus, addressing a critical need in a country where dengue is prevalent. - KIMS is the only site in Odisha and one of 18 sites across India participating in the Phase 3 trial, aiming to recruit over 500 participants in Bhubaneswar. - Previous Phase 1 and 2 trials of DengiAll have shown promising results, paving the way for this late-stage trial to potentially license the vaccine.
